Literature DB >> 31485144

Andexanet Alfa (Andexxa®) for the Reversal of Direct Oral Anticoagulants.

Jayed H Momin, PharmD Candidate, Gregory J Hughes.   

Abstract

Andexanet alfa (Andexxa®) for the reversal of direct oral anticoagulants.

Entities:  

Keywords:  Andexxa; andexanet alfas; antidote; apixaban; bleeding; reversal; rivaroxaban

Year:  2019        PMID： 31485144      PMCID： PMC6705484     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  8 in total

1.  The real decoy: an antidote for factor Xa-directed anticoagulants.

Authors:  Calvin H Yeh; James C Fredenburgh; Jeffrey I Weitz
Journal:  Circ Res       Date:  2013-09-27       Impact factor: 17.367

2.  Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors.

Authors:  Stuart J Connolly; Mark Crowther; John W Eikelboom; C Michael Gibson; John T Curnutte; John H Lawrence; Patrick Yue; Michele D Bronson; Genmin Lu; Pamela B Conley; Peter Verhamme; Jeannot Schmidt; Saskia Middeldorp; Alexander T Cohen; Jan Beyer-Westendorf; Pierre Albaladejo; Jose Lopez-Sendon; Andrew M Demchuk; Daniel J Pallin; Mauricio Concha; Shelly Goodman; Janet Leeds; Sonia Souza; Deborah M Siegal; Elena Zotova; Brandi Meeks; Sadia Ahmad; Juliet Nakamya; Truman J Milling
Journal:  N Engl J Med       Date:  2019-02-07       Impact factor: 91.245

Review 3.  2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.

Authors:  Gordon F Tomaselli; Kenneth W Mahaffey; Adam Cuker; Paul P Dobesh; John U Doherty; John W Eikelboom; Roberta Florido; William Hucker; Roxana Mehran; Steven R Messé; Charles V Pollack; Fatima Rodriguez; Ravindra Sarode; Deborah Siegal; Barbara S Wiggins
Journal:  J Am Coll Cardiol       Date:  2017-12-01       Impact factor: 24.094

4.  Safety, pharmacokinetics, and reversal of apixaban anticoagulation with andexanet alfa.

Authors:  Deborah Siegal; Genmin Lu; Janet M Leeds; Mark Karbarz; Janice Castillo; Vandana Mathur; Athiwat Hutchaleelaha; Uma Sinha; Michael Kitt; Matt McClure; Stanley J Hollenbach; John T Curnutte; Pamela B Conley; Mark Crowther
Journal:  Blood Adv       Date:  2017-09-22

5.  National Trends in Ambulatory Oral Anticoagulant Use.

Authors:  Geoffrey D Barnes; Eleanor Lucas; G Caleb Alexander; Zachary D Goldberger
Journal:  Am J Med       Date:  2015-07-02       Impact factor: 4.965

6.  Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity.

Authors:  Deborah M Siegal; John T Curnutte; Stuart J Connolly; Genmin Lu; Pamela B Conley; Brian L Wiens; Vandana S Mathur; Janice Castillo; Michele D Bronson; Janet M Leeds; Florie A Mar; Alex Gold; Mark A Crowther
Journal:  N Engl J Med       Date:  2015-11-11       Impact factor: 91.245

Review 7.  Andexanet Alfa: First Global Approval.

Authors:  Young-A Heo
Journal:  Drugs       Date:  2018-07       Impact factor: 9.546

Review 8.  Evaluation of bleeding in patients receiving direct oral anticoagulants.

Authors:  Erika L Hellenbart; Kathleen D Faulkenberg; Shannon W Finks
Journal:  Vasc Health Risk Manag       Date:  2017-08-23
  8 in total
  1 in total

1.  Comparison of Enoxaparin and Rivaroxaban in the Prophylaxis of Deep Venous Thrombosis in Arthroplasty.

Authors:  Necati Çiçek; İsmail Ağir; Hacı Bayram Tosun; Abuzer Uludağ; Abdulkadir Sari
Journal:  Emerg Med Int       Date:  2021-11-16       Impact factor: 1.112
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.